Literature DB >> 9347981

Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat.

J W Simpkins1, G Rajakumar, Y Q Zhang, C E Simpkins, D Greenwald, C J Yu, N Bodor, A L Day.   

Abstract

The present study was undertaken to determine if estrogens protect female rats from the neurodegenerative effects of middle cerebral artery (MCA) occlusion. The rats were ovariectomized and 7 or 8 days later various estrogen preparations were administered before or after MCA occlusion. Pretreatment with 17beta-estradiol (17beta-E2) or a brain-targeted 17beta-E2 chemical delivery system (CDS) decreased mortality from 65% in ovariectomized rats to 22% in 17beta-E2-treated and 16% in 17beta-E2 CDS-treated rats. This marked reduction in mortality was accompanied by a reduction in the ischemic area of the brain from 25.6+/-5.7% in the ovariectomized rats to 9.8+/-4% and 9.1+/-4.2% in the 17beta-E2-implanted and the 17beta-E2 CDS-treated rats, respectively. Similarly, pretreatment with the presumed inactive estrogen, 17alpha-estradiol, reduced mortality from 36 to 0% and reduced the ischemic area by 55 to 81%. When administered 40 or 90 minutes after MCA occlusion, 17beta-E2 CDS reduced the area of ischemia by 45 to 90% or 31%, respectively. In summary, the present study provides the first evidence that estrogens exert neuroprotective effects in an animal model of ischemia and suggests that estrogens may be a useful therapy to protect neurons against the neurodegenerative effects of stroke.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347981     DOI: 10.3171/jns.1997.87.5.0724

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  140 in total

1.  Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in Vitro model for assessment of the neuroprotective effects of estrogens.

Authors:  L L Zaulyanov; P S Green; J W Simpkins
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

Review 2.  Estrogen neuroprotection and the critical period hypothesis.

Authors:  Erin Scott; Quan-guang Zhang; Ruimin Wang; Ratna Vadlamudi; Darrell Brann
Journal:  Front Neuroendocrinol       Date:  2011-11-04       Impact factor: 8.606

3.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 4.  Impact of estrogen therapy on Alzheimer's disease: a fork in the road?

Authors:  Roberta D Brinton
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Ovariectomy and 17β-estradiol replacement in rats and mice: a visual demonstration.

Authors:  Jakob O Ström; Annette Theodorsson; Edvin Ingberg; Ida-Maria Isaksson; Elvar Theodorsson
Journal:  J Vis Exp       Date:  2012-06-07       Impact factor: 1.355

Review 6.  Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke.

Authors:  Farida Sohrabji; Amutha Selvamani; Robyn Balden
Journal:  Horm Behav       Date:  2012-06-19       Impact factor: 3.587

7.  Estradiol protects against hippocampal damage and impairments in fear conditioning resulting from transient global ischemia in mice.

Authors:  Jennah L Durham; Katherine A Jordan; Marijke J Devos; Erika K Williams; Noah J Sandstrom
Journal:  Brain Res       Date:  2012-01-17       Impact factor: 3.252

Review 8.  Neuroprotective action of acute estrogens: animal models of brain ischemia and clinical implications.

Authors:  Tomoko Inagaki; Anne M Etgen
Journal:  Steroids       Date:  2013-02-04       Impact factor: 2.668

9.  17alpha-Estradiol is neuroprotective in male and female rats in a model of early brain injury.

Authors:  Jacob McClean; Joseph L Nuñez
Journal:  Exp Neurol       Date:  2007-10-10       Impact factor: 5.330

Review 10.  Sex differences in cognitive impairment and Alzheimer's disease.

Authors:  Rena Li; Meharvan Singh
Journal:  Front Neuroendocrinol       Date:  2014-01-13       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.